Researchers from the Salk Institute in US expanded upon their previous development of a drug candidate, called J147, which takes a different tack by targeting Alzheimer's major risk factor - old age.
In the study, the team showed that the drug candidate worked well in a mouse model of ageing not typically used in Alzheimer's research.
When these mice were treated with J147, they had better memory and cognition, healthier blood vessels in the brain and other improved physiological features.
"We did not predict we'd see this sort of anti-ageing effect, but J147 made old mice look like they were young, based upon a number of physiological parameters," Currais said.
Alzheimer's disease is a progressive brain disorder. It is also the most common cause of dementia in older adults, according to the US National Institutes of Health.
"While most drugs developed in the past 20 years target the amyloid plaque deposits in the brain (which are a hallmark of the disease), none have proven effective in the clinic," said senior author David Schubert, professor at Salk Institute.
Previously, the team found that J147 could prevent and even reverse memory loss and Alzheimer's pathology in mice that have a version of the inherited form of Alzheimer's, the most commonly used mouse model.
However, this form of the disease comprises only about 1 per cent of Alzheimer's cases. For everyone else, old age is the primary risk factor, said Schubert.
The researchers used a comprehensive set of assays to measure the expression of all genes in the brain, as well as over 500 small molecules involved with metabolism in the brains and blood of three groups of the rapidly ageing mice.
The old mice that received J147 performed better on memory and other tests for cognition and also displayed more robust motor movements.
The mice treated with J147 also had fewer pathological signs of Alzheimer's in their brains.
The study was published in the journal Ageing.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
